Company profile
BioTheryX, Inc.
Privately held: no public share price (San Diego clinical-stage biotech (targeted protein degraders, PRODEGY platform); privately held, most recent raise a $92M Series E led by Farallon Capital Management. Not present in the company roster. Sources: https://clinicaltrials.gov/study/NCT06515470 ; https://api.gleif.org/api/v1/lei-records/2549000CDYS5YH6XDR52 ; https://api.gleif.org/api/v1/lei-records/984500EC7LEQEU100570 ; https://www.biotheryx.com/biotheryx-announces-92m-series-e-financing-to-accelerate-development-of-targeted-protein-degradation-pipeline-and-technology-platform-in-oncology/ ; https://www.crunchbase.com/organization/biotheryx Entity resolved by asset-pipeline-v2.)
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | CDK4/6Small molecule | HR+/HER2- Breast Cancer HR+/HER2- Metastatic Breast Cancer |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.